These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 19010911

  • 1. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.
    Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D, Senter PD, Gao C, Wu H, Kinch M, Coats S, Kiener PA, Tice DA.
    Cancer Res; 2008 Nov 15; 68(22):9367-74. PubMed ID: 19010911
    [Abstract] [Full Text] [Related]

  • 2. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
    Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK.
    J Natl Cancer Inst; 2009 Sep 02; 101(17):1193-205. PubMed ID: 19641174
    [Abstract] [Full Text] [Related]

  • 3. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.
    Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS.
    Cancer Res; 2002 May 15; 62(10):2840-7. PubMed ID: 12019162
    [Abstract] [Full Text] [Related]

  • 4. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
    Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA.
    Cancer Res; 2007 Apr 15; 67(8):3927-35. PubMed ID: 17440108
    [Abstract] [Full Text] [Related]

  • 5. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD.
    Bioconjug Chem; 2006 Apr 15; 17(1):114-24. PubMed ID: 16417259
    [Abstract] [Full Text] [Related]

  • 6. Differential EphA2 epitope display on normal versus malignant cells.
    Coffman KT, Hu M, Carles-Kinch K, Tice D, Donacki N, Munyon K, Kifle G, Woods R, Langermann S, Kiener PA, Kinch MS.
    Cancer Res; 2003 Nov 15; 63(22):7907-12. PubMed ID: 14633720
    [Abstract] [Full Text] [Related]

  • 7. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
    Noblitt LW, Bangari DS, Shukla S, Mohammed S, Mittal SK.
    Cancer Gene Ther; 2005 Jan 15; 12(1):46-53. PubMed ID: 15486559
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.
    Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK.
    Clin Cancer Res; 2010 May 01; 16(9):2562-70. PubMed ID: 20388851
    [Abstract] [Full Text] [Related]

  • 10. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
    Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ.
    Clin Cancer Res; 2006 Feb 15; 12(4):1373-82. PubMed ID: 16489096
    [Abstract] [Full Text] [Related]

  • 11. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR, Hinman LM, Beyer CF, Greenberger LM, Lin C, Lindh D, Menendez AT, Wallace R, Durr FE, Upeslacis J.
    Bioconjug Chem; 2005 Feb 15; 16(2):346-53. PubMed ID: 15769088
    [Abstract] [Full Text] [Related]

  • 12. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
    Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Shochat D, Mountain A.
    Bioconjug Chem; 2005 Feb 15; 16(2):354-60. PubMed ID: 15769089
    [Abstract] [Full Text] [Related]

  • 13. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
    Jacobson O, Li Q, Chen H, Niu G, Kiesewetter DO, Xu L, Cook K, Yang G, Dall'Acqua W, Tsui P, Peng L, Chen X.
    J Nucl Med; 2017 Nov 15; 58(11):1838-1844. PubMed ID: 28546337
    [Abstract] [Full Text] [Related]

  • 14. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.
    Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP.
    Clin Cancer Res; 2008 Oct 01; 14(19):6171-80. PubMed ID: 18809969
    [Abstract] [Full Text] [Related]

  • 15. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
    Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA.
    Clin Cancer Res; 2004 Oct 15; 10(20):7063-70. PubMed ID: 15501986
    [Abstract] [Full Text] [Related]

  • 16. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style.
    Parri M, Taddei ML, Bianchini F, Calorini L, Chiarugi P.
    Cancer Res; 2009 Mar 01; 69(5):2072-81. PubMed ID: 19244130
    [Abstract] [Full Text] [Related]

  • 17. Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models.
    Chen Q, Millar HJ, McCabe FL, Manning CD, Steeves R, Lai K, Kellogg B, Lutz RJ, Trikha M, Nakada MT, Anderson GM.
    Clin Cancer Res; 2007 Jun 15; 13(12):3689-95. PubMed ID: 17575234
    [Abstract] [Full Text] [Related]

  • 18. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
    Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, Kerjaschki D, Rettig WJ, Adolf GR.
    Clin Cancer Res; 2008 Jul 15; 14(14):4584-92. PubMed ID: 18628473
    [Abstract] [Full Text] [Related]

  • 19. Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.
    Lee NK, Su Y, Bidlingmaier S, Liu B.
    Mol Cancer Ther; 2019 Jun 15; 18(6):1092-1103. PubMed ID: 30962321
    [Abstract] [Full Text] [Related]

  • 20. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma.
    Asundi J, Reed C, Arca J, McCutcheon K, Ferrando R, Clark S, Luis E, Tien J, Firestein R, Polakis P.
    Clin Cancer Res; 2011 Mar 01; 17(5):965-75. PubMed ID: 21245091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.